----item----
version: 1
id: {7218DB1C-F580-43C5-A55E-96A68E22044A}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/Earnings 2014
parent: {D5B965D3-AC3D-4A7F-90E6-65193022C6B5}
name: Earnings 2014
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: b800772c-acbb-4aa8-a6f5-1307c31da221

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 17937

<p>  <tr> <td><b>Company</b></td> <td><b>Ticker symbol</b></td> <td><b>Country</b></td> <td><b>Sector</b></td> <td><b>Period</b></td> <td><b>Net revenue</b></td> <td><b>% change</b></td> <td><b>Net income/(loss)</b></td> <td><b>Previous net income/(loss)</b></td> <td><b>Date reported</b></td> </tr> <tr> <td><b>Medtronic</b></td> <td>MDT</td> <td>US</td> <td>Cardiovascular, spine, neuromodulation, surgery, diabetes</td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> </tr> <tr> <td>Q4 2014</td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td>20/05/2014</td> </tr> <tr> <td>Q3 2014</td> <td>$4,163 <br></td> <td>3</td> <td>$762</td> <td>$988 <br></td> <td><a>18/02/2014</a></td> </tr> <tr> <td><b>Baxter International</b></td> <td>BAX</td> <td>US</td> <td>Drug delivery, dialysis, plasma-based therapies</td> <td>Q1 2014</td> <td>$3,951</td> <td>15</td> <td>$556</td> <td>$552</td> <td><a>17/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$4,368</td> <td>16</td> <td>$326</td> <td>$494</td> <td>23/01/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$15,259</td> <td>8</td> <td>$2,012</td> <td>$2,326</td> </tr> <tr> <td><b>Biomet</b></td> <td>N/A</td> <td>US</td> <td>Orthopedics</td> <td>Q3 2014</td> <td>$822.5</td> <td>7</td> <td>($65.9 )  </td> <td>($304.5)</td> <td>03/04/2014</td> </tr> <tr> <td>Q2 2014</td> <td>$825.7</td> <td>5</td> <td>$4.9</td> <td>($66.2)</td> <td><a>08/01/2014</a></td> </tr> <tr> <td>Q1 2014</td> <td>$730.7</td> <td>3</td> <td>$31.1</td> <td>($31.5)</td> <td><a>08/10/2013</a></td> </tr> <tr> <td><b>bioMérieux</b></td> <td>BIM</td> <td>France</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>&euro;370.8 ($513.2)</td> <td>3</td> <td>Not given</td> <td>Not given</td> <td><a>23/04/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>&euro;1587.9 ($2197.6)</td> <td>1</td> <td>&euro;165 ($228.4)</td> <td>&euro;134 ($185.5)</td> <td><a>19/03/2014</a></td> </tr> <tr> <td><b>Mindray Medical</b></td> <td>MR</td> <td>China</td> <td>In vitro diagnostics , imaging</td> <td>Q1 2014</td> <td>$264.8</td> <td>9</td> <td>$35.6</td> <td>$57.4</td> <td>05/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$368.4</td> <td>17</td> <td>$75.2</td> <td>$55.8</td> <td><a>03/03/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$1,214.0</td> <td>15</td> <td>$224.8</td> <td>$180.2</td> </tr> <tr> <td><b>HeartWare International</b></td> <td>HTWR</td> <td>US</td> <td>Cardiovascular</td> <td>Q1 2014</td> <td>$66.5</td> <td>35</td> <td>($19.4)</td> <td>($13.0)</td> <td>01/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$53.1</td> <td>62</td> <td>($22.0)</td> <td>($21.1)</td> <td>27/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$207.9</td> <td>87</td> <td>($59.3)</td> <td>($87.7)</td> </tr> <tr> <td><b>Integra Lifesciences</b></td> <td>IART</td> <td>US</td> <td>Surgery, orthopedics</td> <td>Q1 2014</td> <td>$215.1</td> <td>9</td> <td>$2.2</td> <td>($6.0)</td> <td>01/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$220.8</td> <td>3</td> <td>$12.2</td> <td>$12.8</td> <td><a>26/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$836.2</td> <td>1</td> <td>($17.0)</td> <td>$41.2</td> </tr> <tr> <td><b>Wright Medical</b></td> <td>WMGI</td> <td>US</td> <td>Orthopedics</td> <td>Q1 2014</td> <td>$71.1</td> <td>26</td> <td>($30.4)</td> <td>$8.4</td> <td>30/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$67.8</td> <td>16</td> <td>($135.0)</td> <td>$5.4</td> <td><a>25/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$242.3</td> <td>13</td> <td>($273.9)</td> <td>$5.3</td> </tr> <tr> <td><b>Fresenius Medical Care</b></td> <td>FME.DE</td> <td>Germany</td> <td>Dialysis</td> <td>Q1 2014</td> <td>$3,564</td> <td>3</td> <td>$205</td> <td>$225</td> <td>06/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$3,867</td> <td>4</td> <td>$349</td> <td>$257</td> <td><a>25/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$14,160</td> <td>6</td> <td>$1,110</td> <td>$1,118</td> </tr> <tr> <td><b>Teleflex</b></td> <td>TFX</td> <td>US</td> <td>Critical care, surgery, cardiovascular, OEM</td> <td>Q1 2014</td> <td>$438.5</td> <td>6</td> <td>$35.0</td> <td>$27.0</td> <td>30/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$450.5 </td> <td>7</td> <td>$34.8</td> <td>$29.3</td> <td><a>24/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$1,696.3</td> <td>9</td> <td>$150.9</td> <td>($190.1)</td> </tr> <tr> <td><b>Hospira </b></td> <td>HSP</td> <td>US</td> <td>Drug delivery</td> <td>Q1 2014</td> <td>$206.2 (Medication management only)</td> <td>-10</td> <td>$67.9 (group net income)</td> <td>($76.6) (group net loss)</td> <td>30/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$221.7 (Medication Management only)</td> <td>-17</td> <td>$33.5 (group net income)</td> <td>$5.3 (group net income)</td> <td>12/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$769.8 (Medication Management only)</td> <td>-24</td> <td>($8.3) (group net loss)</td> <td>$44.2 (group net income)</td> </tr> <tr> <td><b>LabCorp</b></td> <td>LH</td> <td>US</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>$1,430.7 </td> <td>-1</td> <td>$113.1   </td> <td>$147.2   </td> <td><a>28/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>  $1,437.0 </td> <td>2</td> <td>$126.3   </td> <td>$120.2</td> <td><a>07/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$5,808.3 </td> <td>2</td> <td>$573.8   </td> <td>$583.1   </td> </tr> <tr> <td><b>Sorin</b></td> <td>SRN</td> <td>Italy</td> <td>Cardiovascular</td> <td>Q1 2014</td> <td>&euro;176.3 ($243.8)</td> <td>-1</td> <td>&euro;9.9 ($13.7)</td> <td>&euro;5 ($6.9)</td> <td><a>29/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>&euro;191.8 ($260.2)</td> <td>1</td> <td>&euro;16 ($21.7)</td> <td>&euro;4.8 ($6.5)</td> <td>06/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>&euro;738.5 ($1.00bn)</td> <td>1</td> <td>&euro;49.9 ($67.7)</td> <td>&euro;23.0 ($31.2)</td> </tr> <tr> <td><b>Alere</b></td> <td>ALR</td> <td>US</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>$716.6</td> <td>-3</td> <td>($11.5)</td> <td>$7.2</td> <td><a>29/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$772.3</td> <td>2</td> <td>($9.1)</td> <td>($68.0)</td> <td>06/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$3,029.4</td> <td>7</td> <td>($92.5)</td> <td>($99.5)</td> </tr> <tr> <td><b>Smith &amp; Nephew</b></td> <td>SNN</td> <td>UK</td> <td>Orthopedics, wound care</td> <td>Q1 2014</td> <td>$1,073  </td> <td>0</td> <td>$229 (trading profit)</td> <td>$241 (trading profit)</td> <td>01/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$1,175</td> <td>9</td> <td>$292 (trading profit)</td> <td>$272 (trading profit)</td> <td><a>06/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$4,351</td> <td>5</td> <td>$987 (trading profit)</td> <td>$965 (trading profit)</td> </tr> <tr> <td><b>Thoratec</b></td> <td>THOR</td> <td>US</td> <td>Cardiovascular</td> <td>Q1 2014</td> <td>$125.7</td> <td>7</td> <td>$18.2</td> <td>$18.2</td> <td>06/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$128.2</td> <td>0</td> <td>$13.1</td> <td>($14.4)</td> <td><a>04/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$502.8</td> <td>2</td> <td>$73.3</td> <td>$56.2</td> </tr> <tr> <td><b>Myriad Genetics</b></td> <td>MYGN</td> <td>US</td> <td>In vitro diagnostics</td> <td>Q3 2014</td> <td>$182.9</td> <td>17</td> <td>$36.8</td> <td>$37.9</td> <td>06/05/2014</td> </tr> <tr> <td>Q2 2014</td> <td>$204.1</td> <td>37</td> <td>$50.4</td> <td>$35.0</td> <td><a>04/02/2014</a></td> </tr> <tr> <td>H1 2014</td> <td>$406.5</td> <td>44</td> <td>$105.8</td> <td>$65.2</td> </tr> <tr> <td><b>Boston Scientific</b></td> <td>BSX</td> <td>US</td> <td>Cardiovascular, cardiac rhythm management, surgery</td> <td>Q1 2014</td> <td>$1,774</td> <td>1</td> <td>$133</td> <td>($354)</td> <td><a>29/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,838</td> <td>1</td> <td>$108</td> <td>$60</td> <td><a>04/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$7,143</td> <td>-1</td> <td>($121)</td> <td>($4,068) </td> </tr> <tr> <td><b>Becton Dickinson</b></td> <td>BDX</td> <td>US</td> <td>In vitro diagnostics, surgery, diabetes</td> <td>Q2 2014</td> <td>$2,072</td> <td>4</td> <td>$287</td> <td>$276</td> <td>01/05/2014</td> </tr> <tr> <td>Q1 2014</td> <td>$2,015</td> <td>6</td> <td>$271</td> <td>$625</td> <td><a>04/02/2014</a></td> </tr> <tr> <td><b>Hologic</b></td> <td>HOLX</td> <td>US</td> <td>In vitro diagnostics, imaging, surgery</td> <td>Q2 2014</td> <td>$625.0</td> <td>2</td> <td>($16.8)</td> <td>($51.1)</td> <td>30/04/2014</td> </tr> <tr> <td>Q1 2014</td> <td>$612.4</td> <td>-3</td> <td>($5.4)</td> <td>$3.1</td> <td><a>03/02/2014</a></td> </tr> <tr> <td><b>Edwards Lifesciences</b></td> <td>EW</td> <td>US</td> <td>Heart valves, hemodynamic monitoring</td> <td>Q1 2014</td> <td>$522.4</td> <td>5</td> <td>$60.3</td> <td>$143.9</td> <td><a>24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$536.0</td> <td>5</td> <td>$75.8</td> <td>$91.1</td> <td><a>03/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$2,045.5</td> <td>8</td> <td>$391.7</td> <td>$293.2</td> </tr> <tr> <td><b>CareFusion</b></td> <td>CFN</td> <td>US</td> <td>Infusion pumps, respiratory, surgery, hospital equipment</td> <td>Q3 2014</td> <td>$968</td> <td>7</td> <td>$102</td> <td>$84</td> <td>05/05/2014</td> </tr> <tr> <td>Q2 2014</td> <td>$922</td> <td>1</td> <td>$97</td> <td>$108</td> <td><a>03/02/2014</a></td> </tr> <tr> <td>H1 2014</td> <td>$1,752</td> <td>0</td> <td>$175</td> <td>$192</td> </tr> <tr> <td><b>Quest Diagnostics</b></td> <td>DGX</td> <td>US</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>$1,746</td> <td>-2</td> <td>$111</td> <td>$144</td> <td><a>24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,756 </td> <td>-1</td> <td>$151 </td> <td>$66 </td> <td><a>30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$7,146 </td> <td>-3</td> <td>$883 </td> <td>$592 </td> </tr> <tr> <td><b>Thermo Fisher Scientific</b></td> <td>TMO</td> <td>US</td> <td>In vitro diagnostics, lab services</td> <td>Q1 2014</td> <td>$3,903.5</td> <td>22</td> <td>$543.1  </td> <td>$336.2</td> <td><a>23/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$3,466.90 </td> <td>6</td> <td>$342.10 </td> <td>$376.40 </td> <td><a>30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$13,090.30 </td> <td>5</td> <td>$1,273.30 </td> <td>$1,177.90 </td> </tr> <tr> <td><b>PerkinElmer</b></td> <td>PKI</td> <td>US</td> <td>Neonatal screening, diagnostic imaging, informatics</td> <td>Q1 2014</td> <td>$531.9</td> <td>5</td> <td>$34.2</td> <td>$32.2</td> <td><a>24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$593.30 </td> <td>4</td> <td>$64.50 </td> <td>($15.90)</td> <td><a>30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$2,166.20 </td> <td>2</td> <td>$164.80 </td> <td>$69.90 </td> </tr> <tr> <td><b>CR Bard</b></td> <td>BCR</td> <td>US</td> <td>Vascular, urology, surgery, biopsy devices </td> <td>Q1 2014</td> <td>$799.3</td> <td>8</td> <td>$148.4 </td> <td>$90.7</td> <td><a>22/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$791.30 </td> <td>4</td> <td>$667.50 </td> <td>$128.20 </td> <td><a>30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$3,049 </td> <td>3</td> <td>$689.80 </td> <td>$530.10 </td> </tr> <tr> <td><b>Zimmer</b></td> <td>ZMH</td> <td>US</td> <td>Orthopedics</td> <td>Q1 2014</td> <td>$1,161.5</td> <td>2</td> <td>$221.5</td> <td>$218.6</td> <td><a>24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,241 </td> <td>5</td> <td>$235.90 </td> <td>$152.80 </td> <td><a>30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$4,623 </td> <td>3</td> <td>$761.00 </td> <td>$755.0<br> </td> </tr> <tr> <td><b>Roche Diagnostics</b></td> <td>ROG VX</td> <td>Switzerland</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>CHF2,456 ($2,787)</td> <td>2</td> <td>N/A</td> <td>N/A</td> <td><a>15/04/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>CHF10,476 ($11,650)</td> <td>2</td> <td>N/A</td> <td>N/A</td> <td><a>30/1/14</a></td> </tr> <tr> <td><b>Qiagen</b></td> <td>QGEN</td> <td>The Netherlands</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>$317.4</td> <td>5</td> <td>$53.7</td> <td>$48.1</td> <td>06/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$362.60 </td> <td>5</td> <td>$87.80 </td> <td>$82.80 </td> <td>29/1/14</td> </tr> <tr> <td>Full year 2013</td> <td>$1,306.30 </td> <td>4</td> <td>$275.10 </td> <td>$260.70 </td> </tr> <tr> <td><b>Illumina</b></td> <td>ILMN</td> <td>US</td> <td>Genome sequencing</td> <td>Q1 2014</td> <td>$420.8</td> <td>27</td> <td>$60.0</td> <td>($22.6)</td> <td><a>22/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$387.30 </td> <td>25</td> <td>$80.70 </td> <td>$71.90 </td> <td><a>29/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$1,421.20 </td> <td>24</td> <td>$125.30 </td> <td>$151.30 </td> </tr> <tr> <td><b>Siemens Healthcare</b></td> <td>SIE.DE</td> <td>Germany</td> <td>Diagnostic imaging, in vitro diagnostics</td> <td>Q2 2014</td> <td>&euro;3,256 ($4,467)</td> <td>-1</td> <td>&euro;531 ($728)</td> <td>&euro;445 ($610)</td> <td>07/05/2014</td> </tr> <tr> <td>Q1 2014</td> <td>&euro;3,094 ($4,257)</td> <td>-5</td> <td>&euro;471 ($648)</td> <td>&euro;503 ($692)</td> <td><a>28/01/2014</a></td> </tr> <tr> <td><b>Getinge</b></td> <td>GETI-B.ST</td> <td>Sweden</td> <td>Surgery, hospital products</td> <td>Q1 2014</td> <td>SEK5,632 ($858.5)</td> <td>-1</td> <td>(SEK330) ($50)</td> <td>SEK184 ($28)</td> <td>16/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>SEK7,757 ($882)</td> <td>-1</td> <td>SEK1,181 ($134, EBIT)</td> <td>SEK1,119 ($127, EBIT)</td> <td>28/1/14</td> </tr> <tr> <td>Full year 2013</td> <td>SEK25,395 ($2,886)</td> <td>4</td> <td>SEK2,334 ($265, EBIT)</td> <td>SEK2,384 ($271, EBIT)</td> </tr> <tr> <td><b>Danaher</b></td> <td>DHR</td> <td>US</td> <td>In vitro diagnostics</td> <td>Q1 2014</td> <td>$4,662.7  </td> <td>5</td> <td>$579.7</td> <td>$691.9</td> <td><a>16/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$5,266.70 </td> <td>6</td> <td>$789.30 </td> <td>$630.40 </td> <td><a>28/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$19,118.00 </td> <td>5</td> <td>$2,695.00 </td> <td>$2,392.20 </td> </tr> <tr> <td><b>Intuitive Surgical</b></td> <td>ISRG</td> <td>US</td> <td>Surgery</td> <td>Q1 2014</td> <td>$464.7</td> <td>-24</td> <td>$44.3</td> <td>$188.9</td> <td><a>22/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$576.20 </td> <td>-5</td> <td>$166.20 </td> <td>$174.90 </td> <td><a>27/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$2,265.10 </td> <td>4</td> <td>$671.00 </td> <td>$656.60 </td> </tr> <tr> <td><b>Covidien</b></td> <td>COV</td> <td>Ireland</td> <td>Surgery, vascular, respiratory</td> <td>Q2 2014</td> <td>$2,598</td> <td>3</td> <td>$441</td> <td>$439   </td> <td><a>25/04/2014</a></td> </tr> <tr> <td>Q1 2014</td> <td>$2,639 </td> <td>3</td> <td>$398 </td> <td>$493 </td> <td><a>27/1/14</a></td> </tr> <tr> <td><b>Stryker</b></td> <td>SYK</td> <td>US</td> <td>Orthopedics</td> <td>Q1 2014</td> <td> $2,305 </td> <td>5</td> <td>$70</td> <td>$304</td> <td><a>23/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$2,468 </td> <td>6</td> <td>$386 </td> <td>$270 </td> <td><a>23/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$9,021 </td> <td>4</td> <td>$1,006 </td> <td>$1,298 </td> </tr> <tr> <td><b>Varian Medical Systems</b></td> <td>VAR</td> <td>US</td> <td>Radiotherapy</td> <td>Q2 2014</td> <td>$778.5</td> <td>1</td> <td>$92.7</td> <td>$112.8</td> <td><a>23/04/2014</a></td> </tr> <tr> <td>Q1 2014</td> <td>$712 </td> <td>5</td> <td>$98 </td> <td>$95 </td> <td>22/1/14</td> </tr> <tr> <td><b>Abbot</b></td> <td>ABT</td> <td>US</td> <td>In vitro diagnostics, vascular, diabetes, vision</td> <td>Q1 2014</td> <td>$5,244</td> <td>-2</td> <td>$375</td> <td>$544</td> <td><a>16/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$5,655 </td> <td>0</td> <td>$589 </td> <td>$1,053 </td> <td><a>22/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$21,848 </td> <td>2</td> <td>$2,576 </td> <td>$5,963 </td> </tr> <tr> <td><b>St Jude Medical</b></td> <td>STJ</td> <td>US</td> <td>Cardiovascular, neurostimulation</td> <td>Q1 2014</td> <td>$1,363</td> <td>2</td> <td>$249</td> <td>$223</td> <td><a>16/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,422 </td> <td>4</td> <td>$123 </td> <td>$120 </td> <td><a>22/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$5,501 </td> <td>0</td> <td>$723 </td> <td>$752 </td> </tr> <tr> <td><b>Johnson &amp; Johnson (medical devices &amp; diagnostics division)</b></td> <td>JNJ</td> <td>US</td> <td>Orthopedics, surgery, vision, diabetes, cardiovascular, diagnostics</td> <td>Q1 2014</td> <td>$7,060</td> <td>0</td> <td>$4,727 (group income)</td> <td>$3,497 (group income)</td> <td><a>15/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$7,306 </td> <td>-1</td> <td>$3,519 (group income)</td> <td>$2,567 (group income)</td> <td><a>22/1/14</a></td> </tr> <tr> <td>Full-year 2013</td> <td>$28,490 </td> <td>4</td> <td>$13,831 (group income)</td> <td>$10,853 (group income)</td> </tr> <tr> <td><b>GE Healthcare</b></td> <td>GE</td> <td>UK</td> <td>Diagnostic imaging, IT, molecular medicine</td> <td>Q1 2014</td> <td>$4,198</td> <td>-2</td> <td>$570</td> <td>$595</td> <td>17/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$5,117</td> <td>-1</td> <td>$1,062 </td> <td>$1,021</td> <td><a>17/01/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$18,200</td> <td>0</td> <td>$3,048 </td> <td>$2,920</td> </tr>   </p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 13

Earnings 2014
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 31481

<p> <table> <tr bgcolor="#CCCCCC"> <td><b>Company</b></td> <td valign="middle"><b>Ticker symbol</b></td> <td valign="middle"><b>Country</b></td> <td><b>Sector</b></td> <td><b>Period</b></td> <td><b>Net revenue</b></td> <td><b>% change</b></td> <td><b>Net income/(loss)</b></td> <td><b>Previous net income/(loss)</b></td> <td><b>Date reported</b></td> </tr> <tr> <td rowspan="3"><b>Medtronic</b></td> <td rowspan="3" valign="middle">MDT</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Cardiovascular, spine, neuromodulation, surgery, diabetes</td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> </tr> <tr> <td>Q4 2014</td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> <td>20/05/2014</td> </tr> <tr> <td>Q3 2014</td> <td>$4,163 <br></td> <td>3</td> <td>$762</td> <td>$988 <br></td> <td><a href="http://www.clinica.co.uk/marketsector/cardiovascular/Medtronic-shares-dip-after-bottom-line-drop-350101?autnID=/contentstore/clinica/codex/dc4feca5-98b3-11e3-a09b-cf70e6dc602b.xml">18/02/2014</a></td> </tr> <tr> <td rowspan="3"><b>Baxter International</b></td> <td rowspan="3" valign="middle">BAX</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Drug delivery, dialysis, plasma-based therapies</td> <td>Q1 2014</td> <td>$3,951</td> <td>15</td> <td>$556</td> <td>$552</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-Baxters-sales-rise-15-earnings-beat-forecast-351397?autnID=/contentstore/clinica/codex/5a117178-ca00-11e3-9744-2d401cb09751.xml">17/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$4,368</td> <td>16</td> <td>$326</td> <td>$494</td> <td rowspan="2">23/01/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$15,259</td> <td>8</td> <td>$2,012</td> <td>$2,326</td> </tr> <tr> <td rowspan="3"><b>Biomet</b></td> <td rowspan="3" valign="middle">N/A</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Orthopedics</td> <td>Q3 2014</td> <td>$822.5</td> <td>7</td> <td>($65.9 )  </td> <td>($304.5)</td> <td>03/04/2014</td> </tr> <tr> <td>Q2 2014</td> <td>$825.7</td> <td>5</td> <td>$4.9</td> <td>($66.2)</td> <td><a href="http://www.clinica.co.uk/marketsector/orthopaedics/Biomets-strong-knees-in-Q2-fuel-more-recovery-hopes-349165?autnID=/contentstore/clinica/codex/904e4e28-7859-11e3-8f73-257c4a8c1054.xml">08/01/2014</a></td> </tr> <tr> <td>Q1 2014</td> <td>$730.7</td> <td>3</td> <td>$31.1</td> <td>($31.5)</td> <td><a href="http://www.clinica.co.uk/marketsector/orthopaedics/Biomet-acquires-spine-specialist-as-Q1-hip-and-knee-momentum-improves-347105?autnID=/contentstore/clinica/codex/3aa454f1-3003-11e3-8964-4d1e910a64a6.xml">08/10/2013</a></td> </tr> <tr> <td rowspan="2"><b>bioMérieux</b></td> <td rowspan="2" valign="middle">BIM</td> <td rowspan="2" valign="middle">France</td> <td rowspan="2">In vitro diagnostics</td> <td>Q1 2014</td> <td>&euro;370.8 ($513.2)</td> <td>3</td> <td>Not given</td> <td>Not given</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-Bard-and-bioMerieux-up-while-Intuitive-sales-sink-351426?autnID=/contentstore/clinica/codex/d5bbb4b0-cad5-11e3-9744-2d401cb09751.xml">23/04/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>&euro;1587.9 ($2197.6)</td> <td>1</td> <td>&euro;165 ($228.4)</td> <td>&euro;134 ($185.5)</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/EKF-bulks-up-with-two-deals-bioMerieux-considering-Siemens-swoop-350785?autnID=/contentstore/clinica/codex/aa3335b8-b028-11e3-a09b-cf70e6dc602b.xml">19/03/2014</a></td> </tr> <tr> <td rowspan="3"><b>Mindray Medical</b></td> <td rowspan="3" valign="middle">MR</td> <td rowspan="3" valign="middle">China</td> <td rowspan="3">In vitro diagnostics , imaging</td> <td>Q1 2014</td> <td>$264.8</td> <td>9</td> <td>$35.6</td> <td>$57.4</td> <td>05/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$368.4</td> <td>17</td> <td>$75.2</td> <td>$55.8</td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/other/Business-Bites-Medtronic-wins-major-EU-victory-over-Edwards-while-Infuse-cloud-looms-350456?autnID=/contentstore/clinica/codex/2c2e7ff4-a60c-11e3-a09b-cf70e6dc602b.xml">03/03/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$1,214.0</td> <td>15</td> <td>$224.8</td> <td>$180.2</td> </tr> <tr> <td rowspan="3"><b>HeartWare International</b></td> <td rowspan="3" valign="middle">HTWR</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Cardiovascular</td> <td>Q1 2014</td> <td>$66.5</td> <td>35</td> <td>($19.4)</td> <td>($13.0)</td> <td>01/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$53.1</td> <td>62</td> <td>($22.0)</td> <td>($21.1)</td> <td rowspan="2">27/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$207.9</td> <td>87</td> <td>($59.3)</td> <td>($87.7)</td> </tr> <tr> <td rowspan="3"><b>Integra Lifesciences</b></td> <td rowspan="3" valign="middle">IART</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Surgery, orthopedics</td> <td>Q1 2014</td> <td>$215.1</td> <td>9</td> <td>$2.2</td> <td>($6.0)</td> <td>01/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$220.8</td> <td>3</td> <td>$12.2</td> <td>$12.8</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Q4-EARNINGS-Integras-2013-uninspiring-but-things-looking-up-350269?autnID=/contentstore/clinica/codex/538384c2-9eee-11e3-a09b-cf70e6dc602b.xml">26/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$836.2</td> <td>1</td> <td>($17.0)</td> <td>$41.2</td> </tr> <tr> <td rowspan="3"><b>Wright Medical</b></td> <td rowspan="3" valign="middle">WMGI</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Orthopedics</td> <td>Q1 2014</td> <td>$71.1</td> <td>26</td> <td>($30.4)</td> <td>$8.4</td> <td>30/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$67.8</td> <td>16</td> <td>($135.0)</td> <td>$5.4</td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/orthopaedics/RESULTS-ROUND-UP-Fresenius-slumps-on-poor-earnings-outlook-Wright-looking-bright-350238?autnID=/contentstore/clinica/codex/f0dd0787-9e0c-11e3-a09b-cf70e6dc602b.xml">25/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$242.3</td> <td>13</td> <td>($273.9)</td> <td>$5.3</td> </tr> <tr> <td rowspan="3"><b>Fresenius Medical Care</b></td> <td rowspan="3" valign="middle">FME.DE</td> <td rowspan="3" valign="middle">Germany</td> <td rowspan="3">Dialysis</td> <td>Q1 2014</td> <td>$3,564</td> <td>3</td> <td>$205</td> <td>$225</td> <td>06/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$3,867</td> <td>4</td> <td>$349</td> <td>$257</td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/orthopaedics/RESULTS-ROUND-UP-Fresenius-slumps-on-poor-earnings-outlook-Wright-looking-bright-350238?autnID=/contentstore/clinica/codex/f0dd0787-9e0c-11e3-a09b-cf70e6dc602b.xml">25/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$14,160</td> <td>6</td> <td>$1,110</td> <td>$1,118</td> </tr> <tr> <td rowspan="3"><b>Teleflex</b></td> <td rowspan="3" valign="middle">TFX</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Critical care, surgery, cardiovascular, OEM</td> <td>Q1 2014</td> <td>$438.5</td> <td>6</td> <td>$35.0</td> <td>$27.0</td> <td>30/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$450.5 </td> <td>7</td> <td>$34.8</td> <td>$29.3</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Q4-EARNINGS-Teleflex-finishes-2013-strongly-but-tough-2014-awaits-350210?autnID=/contentstore/clinica/codex/43147d17-9d44-11e3-a09b-cf70e6dc602b.xml">24/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$1,696.3</td> <td>9</td> <td>$150.9</td> <td>($190.1)</td> </tr> <tr> <td rowspan="3"><b>Hospira </b></td> <td rowspan="3" valign="middle">HSP</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Drug delivery</td> <td>Q1 2014</td> <td>$206.2 (Medication management only)</td> <td>-10</td> <td>$67.9 (group net income)</td> <td>($76.6) (group net loss)</td> <td>30/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$221.7 (Medication Management only)</td> <td>-17</td> <td>$33.5 (group net income)</td> <td>$5.3 (group net income)</td> <td rowspan="2">12/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$769.8 (Medication Management only)</td> <td>-24</td> <td>($8.3) (group net loss)</td> <td>$44.2 (group net income)</td> </tr> <tr> <td rowspan="3"><b>LabCorp</b></td> <td rowspan="3" valign="middle">LH</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics</td> <td>Q1 2014</td> <td>$1,430.7 </td> <td>-1</td> <td>$113.1   </td> <td>$147.2   </td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-Rainy-days-for-LabCorp-351504">28/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>  $1,437.0 </td> <td>2</td> <td>$126.3   </td> <td>$120.2</td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/ivds/Business-Bites-GE-offloads-Breas-one-down-in-Myriad-lawsuit-list-349947?autnID=/contentstore/clinica/codex/b4a09fa1-9249-11e3-a09b-cf70e6dc602b.xml">07/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$5,808.3 </td> <td>2</td> <td>$573.8   </td> <td>$583.1   </td> </tr> <tr> <td rowspan="3"><b>Sorin</b></td> <td rowspan="3" valign="middle">SRN</td> <td rowspan="3" valign="middle">Italy</td> <td rowspan="3">Cardiovascular</td> <td>Q1 2014</td> <td>&euro;176.3 ($243.8)</td> <td>-1</td> <td>&euro;9.9 ($13.7)</td> <td>&euro;5 ($6.9)</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/Q1-EARNINGS-Boston-loses-rhythm-Alere-Sorin-351528">29/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>&euro;191.8 ($260.2)</td> <td>1</td> <td>&euro;16 ($21.7)</td> <td>&euro;4.8 ($6.5)</td> <td rowspan="2">06/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>&euro;738.5 ($1.00bn)</td> <td>1</td> <td>&euro;49.9 ($67.7)</td> <td>&euro;23.0 ($31.2)</td> </tr> <tr> <td rowspan="3"><b>Alere</b></td> <td rowspan="3" valign="middle">ALR</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics</td> <td>Q1 2014</td> <td>$716.6</td> <td>-3</td> <td>($11.5)</td> <td>$7.2</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/Q1-EARNINGS-Boston-loses-rhythm-Alere-Sorin-351528">29/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$772.3</td> <td>2</td> <td>($9.1)</td> <td>($68.0)</td> <td rowspan="2">06/02/2014</td> </tr> <tr> <td>Full year 2013</td> <td>$3,029.4</td> <td>7</td> <td>($92.5)</td> <td>($99.5)</td> </tr> <tr> <td rowspan="3"><b>Smith &amp; Nephew</b></td> <td rowspan="3" valign="middle">SNN</td> <td rowspan="3" valign="middle">UK</td> <td rowspan="3">Orthopedics, wound care</td> <td>Q1 2014</td> <td>$1,073  </td> <td>0</td> <td>$229 (trading profit)</td> <td>$241 (trading profit)</td> <td>01/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$1,175</td> <td>9</td> <td>$292 (trading profit)</td> <td>$272 (trading profit)</td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/surgicalwoundcare/Q4-EARNINGS-SandN-not-so-weak-at-the-knees-in-Q4-349867?autnID=/contentstore/clinica/codex/9dd700da-8f47-11e3-a09b-cf70e6dc602b.xml">06/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$4,351</td> <td>5</td> <td>$987 (trading profit)</td> <td>$965 (trading profit)</td> </tr> <tr> <td rowspan="3"><b>Thoratec</b></td> <td rowspan="3" valign="middle">THOR</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Cardiovascular</td> <td>Q1 2014</td> <td>$125.7</td> <td>7</td> <td>$18.2</td> <td>$18.2</td> <td>06/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$128.2</td> <td>0</td> <td>$13.1</td> <td>($14.4)</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/manda/RESULTS-ROUND-UP-Boston-turnaround-sputtering-Myriad-makes-mockery-of-analyst-forecasts-349828?autnID=/contentstore/clinica/codex/86460db0-8e5c-11e3-a09b-cf70e6dc602b.xml">04/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$502.8</td> <td>2</td> <td>$73.3</td> <td>$56.2</td> </tr> <tr> <td rowspan="3"><b>Myriad Genetics</b></td> <td rowspan="3" valign="middle">MYGN</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics</td> <td>Q3 2014</td> <td>$182.9</td> <td>17</td> <td>$36.8</td> <td>$37.9</td> <td>06/05/2014</td> </tr> <tr> <td>Q2 2014</td> <td>$204.1</td> <td>37</td> <td>$50.4</td> <td>$35.0</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/manda/RESULTS-ROUND-UP-Boston-turnaround-sputtering-Myriad-makes-mockery-of-analyst-forecasts-349828?autnID=/contentstore/clinica/codex/86460db0-8e5c-11e3-a09b-cf70e6dc602b.xml">04/02/2014</a></td> </tr> <tr> <td>H1 2014</td> <td>$406.5</td> <td>44</td> <td>$105.8</td> <td>$65.2</td> </tr> <tr> <td rowspan="3"><b>Boston Scientific</b></td> <td rowspan="3" valign="middle">BSX</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Cardiovascular, cardiac rhythm management, surgery</td> <td>Q1 2014</td> <td>$1,774</td> <td>1</td> <td>$133</td> <td>($354)</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/Q1-EARNINGS-Boston-loses-rhythm-Alere-Sorin-351528">29/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,838</td> <td>1</td> <td>$108</td> <td>$60</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/manda/RESULTS-ROUND-UP-Boston-turnaround-sputtering-Myriad-makes-mockery-of-analyst-forecasts-349828?autnID=/contentstore/clinica/codex/86460db0-8e5c-11e3-a09b-cf70e6dc602b.xml">04/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$7,143</td> <td>-1</td> <td>($121)</td> <td>($4,068) </td> </tr> <tr> <td rowspan="2"><b>Becton Dickinson</b></td> <td rowspan="2" valign="middle">BDX</td> <td rowspan="2" valign="middle">US</td> <td rowspan="2">In vitro diagnostics, surgery, diabetes</td> <td>Q2 2014</td> <td>$2,072</td> <td>4</td> <td>$287</td> <td>$276</td> <td>01/05/2014</td> </tr> <tr> <td>Q1 2014</td> <td>$2,015</td> <td>6</td> <td>$271</td> <td>$625</td> <td><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Hologic-and-Edwards-show-encouraging-signs-349815?autnID=/contentstore/clinica/codex/85591653-8db2-11e3-a09b-cf70e6dc602b.xml">04/02/2014</a></td> </tr> <tr> <td rowspan="2"><b>Hologic</b></td> <td rowspan="2" valign="middle">HOLX</td> <td rowspan="2" valign="middle">US</td> <td rowspan="2">In vitro diagnostics, imaging, surgery</td> <td>Q2 2014</td> <td>$625.0</td> <td>2</td> <td>($16.8)</td> <td>($51.1)</td> <td>30/04/2014</td> </tr> <tr> <td>Q1 2014</td> <td>$612.4</td> <td>-3</td> <td>($5.4)</td> <td>$3.1</td> <td><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Hologic-and-Edwards-show-encouraging-signs-349815?autnID=/contentstore/clinica/codex/85591653-8db2-11e3-a09b-cf70e6dc602b.xml">03/02/2014</a></td> </tr> <tr> <td rowspan="3"><b>Edwards Lifesciences</b></td> <td rowspan="3" valign="middle">EW</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Heart valves, hemodynamic monitoring</td> <td>Q1 2014</td> <td>$522.4</td> <td>5</td> <td>$60.3</td> <td>$143.9</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-EW-PKI-DGX-351459">24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$536.0</td> <td>5</td> <td>$75.8</td> <td>$91.1</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Hologic-and-Edwards-show-encouraging-signs-349815?autnID=/contentstore/clinica/codex/85591653-8db2-11e3-a09b-cf70e6dc602b.xml">03/02/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$2,045.5</td> <td>8</td> <td>$391.7</td> <td>$293.2</td> </tr> <tr> <td rowspan="3"><b>CareFusion</b></td> <td rowspan="3" valign="middle">CFN</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Infusion pumps, respiratory, surgery, hospital equipment</td> <td>Q3 2014</td> <td>$968</td> <td>7</td> <td>$102</td> <td>$84</td> <td>05/05/2014</td> </tr> <tr> <td>Q2 2014</td> <td>$922</td> <td>1</td> <td>$97</td> <td>$108</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Hologic-and-Edwards-show-encouraging-signs-349815?autnID=/contentstore/clinica/codex/85591653-8db2-11e3-a09b-cf70e6dc602b.xml">03/02/2014</a></td> </tr> <tr> <td>H1 2014</td> <td>$1,752</td> <td>0</td> <td>$175</td> <td>$192</td> </tr> <tr> <td rowspan="3"><b>Quest Diagnostics</b></td> <td rowspan="3" valign="middle">DGX</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics</td> <td>Q1 2014</td> <td>$1,746</td> <td>-2</td> <td>$111</td> <td>$144</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-EW-PKI-DGX-351459">24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,756 </td> <td>-1</td> <td>$151 </td> <td>$66 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Quest-keeps-on-restructuring-Thermo-high-on-Life-Zimmers-knees-up-349730?autnID=/contentstore/clinica/codex/d2514ac1-8a70-11e3-a09b-cf70e6dc602b.xml">30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$7,146 </td> <td>-3</td> <td>$883 </td> <td>$592 </td> </tr> <tr> <td rowspan="3"><b>Thermo Fisher Scientific</b></td> <td rowspan="3" valign="middle">TMO</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics, lab services</td> <td>Q1 2014</td> <td>$3,903.5</td> <td>22</td> <td>$543.1  </td> <td>$336.2</td> <td><a href="http://www.clinica.co.uk/business/financials/EARNINGS-ROUND-UP-ILMN-SYK-TMO-VAR-351441">23/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$3,466.90 </td> <td>6</td> <td>$342.10 </td> <td>$376.40 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Quest-keeps-on-restructuring-Thermo-high-on-Life-Zimmers-knees-up-349730?autnID=/contentstore/clinica/codex/d2514ac1-8a70-11e3-a09b-cf70e6dc602b.xml">30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$13,090.30 </td> <td>5</td> <td>$1,273.30 </td> <td>$1,177.90 </td> </tr> <tr> <td rowspan="3"><b>PerkinElmer</b></td> <td rowspan="3" valign="middle">PKI</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Neonatal screening, diagnostic imaging, informatics</td> <td>Q1 2014</td> <td>$531.9</td> <td>5</td> <td>$34.2</td> <td>$32.2</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-EW-PKI-DGX-351459">24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$593.30 </td> <td>4</td> <td>$64.50 </td> <td>($15.90)</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Quest-keeps-on-restructuring-Thermo-high-on-Life-Zimmers-knees-up-349730?autnID=/contentstore/clinica/codex/d2514ac1-8a70-11e3-a09b-cf70e6dc602b.xml">30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$2,166.20 </td> <td>2</td> <td>$164.80 </td> <td>$69.90 </td> </tr> <tr> <td rowspan="3"><b>CR Bard</b></td> <td rowspan="3" valign="middle">BCR</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Vascular, urology, surgery, biopsy devices </td> <td>Q1 2014</td> <td>$799.3</td> <td>8</td> <td>$148.4 </td> <td>$90.7</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-Bard-and-bioMerieux-up-while-Intuitive-sales-sink-351426?autnID=/contentstore/clinica/codex/d5bbb4b0-cad5-11e3-9744-2d401cb09751.xml">22/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$791.30 </td> <td>4</td> <td>$667.50 </td> <td>$128.20 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Quest-keeps-on-restructuring-Thermo-high-on-Life-Zimmers-knees-up-349730?autnID=/contentstore/clinica/codex/d2514ac1-8a70-11e3-a09b-cf70e6dc602b.xml">30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$3,049 </td> <td>3</td> <td>$689.80 </td> <td>$530.10 </td> </tr> <tr> <td rowspan="3"><b>Zimmer</b></td> <td rowspan="3" valign="middle">ZMH</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Orthopedics</td> <td>Q1 2014</td> <td>$1,161.5</td> <td>2</td> <td>$221.5</td> <td>$218.6</td> <td><a href="http://www.clinica.co.uk/marketsector/orthopaedics/Zimmer-in-frame-for-number-two-ortho-spot-with-13bn-Biomet-buy-351443?autnID=/contentstore/clinica/codex/2dfae6c9-cbba-11e3-9744-2d401cb09751.xml">24/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,241 </td> <td>5</td> <td>$235.90 </td> <td>$152.80 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Quest-keeps-on-restructuring-Thermo-high-on-Life-Zimmers-knees-up-349730?autnID=/contentstore/clinica/codex/d2514ac1-8a70-11e3-a09b-cf70e6dc602b.xml">30/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$4,623 </td> <td>3</td> <td>$761.00 </td> <td>$755.0<br> </td> </tr> <tr> <td rowspan="2"><b>Roche Diagnostics</b></td> <td rowspan="2" valign="middle">ROG VX</td> <td rowspan="2" valign="middle">Switzerland</td> <td rowspan="2">In vitro diagnostics</td> <td>Q1 2014</td> <td>CHF2,456 ($2,787)</td> <td>2</td> <td>N/A</td> <td>N/A</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/Roche-Diagnostics-makes-solid-start-to-the-year-351320?autnID=/contentstore/clinica/codex/4268e0a8-c489-11e3-9744-2d401cb09751.xml">15/04/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>CHF10,476 ($11,650)</td> <td>2</td> <td>N/A</td> <td>N/A</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/Q4-EARNINGS-Roche-stock-stutters-on-weak-profit-outlook-349684?autnID=/contentstore/clinica/codex/7348534f-899c-11e3-a09b-cf70e6dc602b.xml">30/1/14</a></td> </tr> <tr> <td rowspan="3"><b>Qiagen</b></td> <td rowspan="3" valign="middle">QGEN</td> <td rowspan="3" valign="middle">The Netherlands</td> <td rowspan="3">In vitro diagnostics</td> <td>Q1 2014</td> <td>$317.4</td> <td>5</td> <td>$53.7</td> <td>$48.1</td> <td>06/05/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$362.60 </td> <td>5</td> <td>$87.80 </td> <td>$82.80 </td> <td rowspan="2">29/1/14</td> </tr> <tr> <td>Full year 2013</td> <td>$1,306.30 </td> <td>4</td> <td>$275.10 </td> <td>$260.70 </td> </tr> <tr> <td rowspan="3"><b>Illumina</b></td> <td rowspan="3" valign="middle">ILMN</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Genome sequencing</td> <td>Q1 2014</td> <td>$420.8</td> <td>27</td> <td>$60.0</td> <td>($22.6)</td> <td><a href="http://www.clinica.co.uk/business/financials/EARNINGS-ROUND-UP-ILMN-SYK-TMO-VAR-351441">22/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$387.30 </td> <td>25</td> <td>$80.70 </td> <td>$71.90 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/ivds/Q4-EARNINGS-Illuminas-stock-sitting-pretty-after-Q4-349652?autnID=/contentstore/clinica/codex/e76eaefb-88dc-11e3-a09b-cf70e6dc602b.xml">29/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$1,421.20 </td> <td>24</td> <td>$125.30 </td> <td>$151.30 </td> </tr> <tr> <td rowspan="2"><b>Siemens Healthcare</b></td> <td rowspan="2" valign="middle">SIE.DE</td> <td rowspan="2" valign="middle">Germany</td> <td rowspan="2">Diagnostic imaging, in vitro diagnostics</td> <td>Q2 2014</td> <td>&euro;3,256 ($4,467)</td> <td>-1</td> <td>&euro;531 ($728)</td> <td>&euro;445 ($610)</td> <td>07/05/2014</td> </tr> <tr> <td>Q1 2014</td> <td>&euro;3,094 ($4,257)</td> <td>-5</td> <td>&euro;471 ($648)</td> <td>&euro;503 ($692)</td> <td><a href="http://www.clinica.co.uk/business/financials/Clinica-100-sneak-peek-Siemens-could-leapfrog-GE-to-second-place-350175?autnID=/contentstore/clinica/codex/d7b71792-9a18-11e3-a09b-cf70e6dc602b.xml">28/01/2014</a></td> </tr> <tr> <td rowspan="3"><b>Getinge</b></td> <td rowspan="3" valign="middle">GETI-B.ST</td> <td rowspan="3" valign="middle">Sweden</td> <td rowspan="3">Surgery, hospital products</td> <td>Q1 2014</td> <td>SEK5,632 ($858.5)</td> <td>-1</td> <td>(SEK330) ($50)</td> <td>SEK184 ($28)</td> <td>16/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>SEK7,757 ($882)</td> <td>-1</td> <td>SEK1,181 ($134, EBIT)</td> <td>SEK1,119 ($127, EBIT)</td> <td rowspan="2">28/1/14</td> </tr> <tr> <td>Full year 2013</td> <td>SEK25,395 ($2,886)</td> <td>4</td> <td>SEK2,334 ($265, EBIT)</td> <td>SEK2,384 ($271, EBIT)</td> </tr> <tr> <td rowspan="3"><b>Danaher</b></td> <td rowspan="3" valign="middle">DHR</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics</td> <td>Q1 2014</td> <td>$4,662.7  </td> <td>5</td> <td>$579.7</td> <td>$691.9</td> <td><a href="http://www.clinica.co.uk/marketsector/ivds/Q1-EARNINGS-Danahers-CEO-change-overshadows-ho-hum-Q1-351369?autnID=/contentstore/clinica/codex/d10d3103-c62c-11e3-9744-2d401cb09751.xml">16/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$5,266.70 </td> <td>6</td> <td>$789.30 </td> <td>$630.40 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Q4-EARNINGS-Danaher-in-line-but-guidance-disappoints-349628?autnID=/contentstore/clinica/codex/3c513ea5-882d-11e3-a09b-cf70e6dc602b.xml">28/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$19,118.00 </td> <td>5</td> <td>$2,695.00 </td> <td>$2,392.20 </td> </tr> <tr> <td rowspan="3"><b>Intuitive Surgical</b></td> <td rowspan="3" valign="middle">ISRG</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Surgery</td> <td>Q1 2014</td> <td>$464.7</td> <td>-24</td> <td>$44.3</td> <td>$188.9</td> <td><a href="http://www.clinica.co.uk/business/financials/Q1-EARNINGS-Bard-and-bioMerieux-up-while-Intuitive-sales-sink-351426?autnID=/contentstore/clinica/codex/d5bbb4b0-cad5-11e3-9744-2d401cb09751.xml">22/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$576.20 </td> <td>-5</td> <td>$166.20 </td> <td>$174.90 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/manda/Q4-EARNINGS-Intuitive-shares-slump-as-sales-dip-349611?autnID=/contentstore/clinica/codex/7745c422-876e-11e3-a09b-cf70e6dc602b.xml">27/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$2,265.10 </td> <td>4</td> <td>$671.00 </td> <td>$656.60 </td> </tr> <tr> <td rowspan="2"><b>Covidien</b></td> <td rowspan="2" valign="middle">COV</td> <td rowspan="2" valign="middle">Ireland</td> <td rowspan="2">Surgery, vascular, respiratory</td> <td>Q2 2014</td> <td>$2,598</td> <td>3</td> <td>$441</td> <td>$439   </td> <td><a href="http://www.clinica.co.uk/business/financials/Q2-EARNINGS-Covidien-predicts-Q3-double-digit-EPS-growth-351476">25/04/2014</a></td> </tr> <tr> <td>Q1 2014</td> <td>$2,639 </td> <td>3</td> <td>$398 </td> <td>$493 </td> <td><a href="http://www.clinica.co.uk/business/financials/RESULTS-ROUND-UP-Covidiens-Q1-a-good-start-349608?autnID=/contentstore/clinica/codex/af282273-8760-11e3-a09b-cf70e6dc602b.xml">27/1/14</a></td> </tr> <tr> <td rowspan="3"><b>Stryker</b></td> <td rowspan="3" valign="middle">SYK</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Orthopedics</td> <td>Q1 2014</td> <td> $2,305 </td> <td>5</td> <td>$70</td> <td>$304</td> <td><a href="http://www.clinica.co.uk/business/financials/EARNINGS-ROUND-UP-ILMN-SYK-TMO-VAR-351441">23/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$2,468 </td> <td>6</td> <td>$386 </td> <td>$270 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/marketsector/orthopaedics/Q4-EARNINGS-Stryker-stocks-boosted-by-solid-Q4-end-349554?autnID=/contentstore/clinica/codex/d0879e8a-8447-11e3-a09b-cf70e6dc602b.xml">23/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$9,021 </td> <td>4</td> <td>$1,006 </td> <td>$1,298 </td> </tr> <tr> <td rowspan="2"><b>Varian Medical Systems</b></td> <td rowspan="2" valign="middle">VAR</td> <td rowspan="2" valign="middle">US</td> <td rowspan="2">Radiotherapy</td> <td>Q2 2014</td> <td>$778.5</td> <td>1</td> <td>$92.7</td> <td>$112.8</td> <td><a href="http://www.clinica.co.uk/business/financials/EARNINGS-ROUND-UP-ILMN-SYK-TMO-VAR-351441">23/04/2014</a></td> </tr> <tr> <td>Q1 2014</td> <td>$712 </td> <td>5</td> <td>$98 </td> <td>$95 </td> <td>22/1/14</td> </tr> <tr> <td rowspan="3"><b>Abbot</b></td> <td rowspan="3" valign="middle">ABT</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">In vitro diagnostics, vascular, diabetes, vision</td> <td>Q1 2014</td> <td>$5,244</td> <td>-2</td> <td>$375</td> <td>$544</td> <td><a href="http://www.clinica.co.uk/home/news/Q1-EARNINGS-Mixed-fortunes-for-Abbott-St-Jude-351357?autnID=/contentstore/clinica/codex/bae57082-c56e-11e3-9744-2d401cb09751.xml">16/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$5,655 </td> <td>0</td> <td>$589 </td> <td>$1,053 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Q4-EARNINGS-Abbott-and-St-Jude-in-line-349531?autnID=/contentstore/clinica/codex/3035eb0d-837c-11e3-a09b-cf70e6dc602b.xml">22/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$21,848 </td> <td>2</td> <td>$2,576 </td> <td>$5,963 </td> </tr> <tr> <td rowspan="3"><b>St Jude Medical</b></td> <td rowspan="3" valign="middle">STJ</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Cardiovascular, neurostimulation</td> <td>Q1 2014</td> <td>$1,363</td> <td>2</td> <td>$249</td> <td>$223</td> <td><a href="http://www.clinica.co.uk/home/news/Q1-EARNINGS-Mixed-fortunes-for-Abbott-St-Jude-351357?autnID=/contentstore/clinica/codex/bae57082-c56e-11e3-9744-2d401cb09751.xml">16/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$1,422 </td> <td>4</td> <td>$123 </td> <td>$120 </td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Q4-EARNINGS-Abbott-and-St-Jude-in-line-349531?autnID=/contentstore/clinica/codex/3035eb0d-837c-11e3-a09b-cf70e6dc602b.xml">22/1/14</a></td> </tr> <tr> <td>Full year 2013</td> <td>$5,501 </td> <td>0</td> <td>$723 </td> <td>$752 </td> </tr> <tr> <td rowspan="3"><b>Johnson &amp; Johnson (medical devices &amp; diagnostics division)</b></td> <td rowspan="3" valign="middle">JNJ</td> <td rowspan="3" valign="middle">US</td> <td rowspan="3">Orthopedics, surgery, vision, diabetes, cardiovascular, diagnostics</td> <td>Q1 2014</td> <td>$7,060</td> <td>0</td> <td>$4,727 (group income)</td> <td>$3,497 (group income)</td> <td><a href="http://www.clinica.co.uk/home/Q1-EARNINGS-JandJs-pharma-sales-overtake-devices-351342?autnID=/contentstore/clinica/codex/ff559f9f-c54a-11e3-9744-2d401cb09751.xml">15/04/2014</a></td> </tr> <tr> <td>Q4 2013</td> <td>$7,306 </td> <td>-1</td> <td>$3,519 (group income)</td> <td>$2,567 (group income)</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Q4-EARNINGS-drugs-save-JandJ-again-as-device-sales-dip-349515?autnID=/contentstore/clinica/codex/b58c665d-834b-11e3-a09b-cf70e6dc602b.xml">22/1/14</a></td> </tr> <tr> <td>Full-year 2013</td> <td>$28,490 </td> <td>4</td> <td>$13,831 (group income)</td> <td>$10,853 (group income)</td> </tr> <tr> <td rowspan="3"><b>GE Healthcare</b></td> <td rowspan="3" valign="middle">GE</td> <td rowspan="3" valign="middle">UK</td> <td rowspan="3">Diagnostic imaging, IT, molecular medicine</td> <td>Q1 2014</td> <td>$4,198</td> <td>-2</td> <td>$570</td> <td>$595</td> <td>17/04/2014</td> </tr> <tr> <td>Q4 2013</td> <td>$5,117</td> <td>-1</td> <td>$1,062 </td> <td>$1,021</td> <td rowspan="2"><a href="http://www.clinica.co.uk/business/financials/Clinica-100-sneak-peek-Siemens-could-leapfrog-GE-to-second-place-350175?autnID=/contentstore/clinica/codex/d7b71792-9a18-11e3-a09b-cf70e6dc602b.xml">17/01/2014</a></td> </tr> <tr> <td>Full year 2013</td> <td>$18,200</td> <td>0</td> <td>$3,048 </td> <td>$2,920</td> </tr> </table>  </p> 
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 13

Earnings 2014
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20160622T191351
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT062829
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 13

Earnings 2014
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

349922
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T192250Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

b800772c-acbb-4aa8-a6f5-1307c31da221
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T231351Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
